AKT1 and Hyperglycemia: Consistent with expectations based on mechanism and on clinical trial data, hyperglycemia and hyperglycemia‐related treatment disruption was common in PI3K‐α, AKT and Pan‐PI3K inhibitors but not in other selective PI3k inhibitors.